Dr. Reddy’s Labs Q4 PAT may dip 4.8% YoY to Rs. 300 cr: HDFC Securities

HDFC Securities has come out with its fourth quarter (Jan-March’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Dr. Reddy’s Labs to report net profit at Rs. 300 crore down 4.8% year-on-year (down 11% quarter-on-quarter).

Net Sales are expected to increase by 1 percent Y-o-Y (down 5.7 percent Q-o-Q) to Rs. 3,590 crore, according to HDFC Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 20.7 percent Y-o-Y (down 8.4 percent Q-o-Q) to Rs. 700 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.